全文获取类型
收费全文 | 14812篇 |
免费 | 685篇 |
国内免费 | 96篇 |
专业分类
耳鼻咽喉 | 221篇 |
儿科学 | 176篇 |
妇产科学 | 247篇 |
基础医学 | 1787篇 |
口腔科学 | 351篇 |
临床医学 | 799篇 |
内科学 | 4069篇 |
皮肤病学 | 281篇 |
神经病学 | 1224篇 |
特种医学 | 607篇 |
外科学 | 2520篇 |
综合类 | 32篇 |
一般理论 | 3篇 |
预防医学 | 440篇 |
眼科学 | 225篇 |
药学 | 848篇 |
中国医学 | 32篇 |
肿瘤学 | 1731篇 |
出版年
2023年 | 83篇 |
2022年 | 61篇 |
2021年 | 262篇 |
2020年 | 165篇 |
2019年 | 240篇 |
2018年 | 293篇 |
2017年 | 244篇 |
2016年 | 260篇 |
2015年 | 316篇 |
2014年 | 403篇 |
2013年 | 486篇 |
2012年 | 835篇 |
2011年 | 893篇 |
2010年 | 559篇 |
2009年 | 485篇 |
2008年 | 875篇 |
2007年 | 946篇 |
2006年 | 915篇 |
2005年 | 935篇 |
2004年 | 963篇 |
2003年 | 909篇 |
2002年 | 934篇 |
2001年 | 310篇 |
2000年 | 301篇 |
1999年 | 288篇 |
1998年 | 179篇 |
1997年 | 148篇 |
1996年 | 128篇 |
1995年 | 127篇 |
1994年 | 111篇 |
1993年 | 109篇 |
1992年 | 202篇 |
1991年 | 200篇 |
1990年 | 188篇 |
1989年 | 161篇 |
1988年 | 151篇 |
1987年 | 119篇 |
1986年 | 133篇 |
1985年 | 97篇 |
1984年 | 64篇 |
1983年 | 61篇 |
1982年 | 43篇 |
1981年 | 32篇 |
1980年 | 33篇 |
1979年 | 50篇 |
1978年 | 27篇 |
1977年 | 32篇 |
1975年 | 24篇 |
1973年 | 28篇 |
1970年 | 27篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
1.
Tomoe Koizumi PhD Yodo Sugishita MD PhD Yuki Suzuki-Takahashi MD PhD Kazuko Nara MA Tomoko Miyagawa MA Misako Nakajima MA Kouhei Sugimoto MD PhD Manabu Futamura MD PhD Tatsuro Furui MD PhD Yasushi Takai MD PhD Hiroshi Matsumoto MD PhD Hideko Yamauchi MD Shinji Ohno MD PhD Akemi Kataoka MD PhD Kiyotaka Kawai MD PhD Eisuke Fukuma MD PhD Hiroko Nogi MD PhD Koichiro Tsugawa MD PhD Nao Suzuki MD PhD 《Cancer》2023,129(16):2568-2580
2.
Thomas Fuchs-Buder Sorin J. Brull Malin Jonsson Fagerlund J. Ross Renew Guy Cammu Glenn S. Murphy Michiel Warlé Matias Vested Béla Fülesdi Reka Nemes Malachy O. Columb Daniela Damian Peter J. Davis Hajime Iwasaki Lars I. Eriksson 《Acta anaesthesiologica Scandinavica》2023,67(8):994-1017
The set of guidelines for good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents was developed following an international consensus conference in Copenhagen in 1996 (Viby-Mogensen et al., Acta Anaesthesiol Scand 1996, 40 , 59–74); the guidelines were later revised and updated following the second consensus conference in Stockholm in 2005 (Fuchs-Buder et al., Acta Anaesthesiol Scand 2007, 51 , 789–808). In view of new devices and further development of monitoring technologies that emerged since then, (e.g., electromyography, three-dimensional acceleromyography, kinemyography) as well as novel compounds (e.g., sugammadex) a review and update of these recommendations became necessary. The intent of these revised guidelines is to continue to help clinical researchers to conduct high-quality work and advance the field by enhancing the standards, consistency, and comparability of clinical studies. There is growing awareness of the importance of consensus-based reporting standards in clinical trials and observational studies. Such global initiatives are necessary in order to minimize heterogeneous and inadequate data reporting and to improve clarity and comparability between different studies and study cohorts. Variations in definitions of endpoints or outcome variables can introduce confusion and difficulties in interpretation of data, but more importantly, it may preclude building of an adequate body of evidence to achieve reliable conclusions and recommendations. Clinical research in neuromuscular pharmacology and physiology is no exception. 相似文献
3.
Tetsuo Yamaguchi Daisuke Ueshima Makoto Utsunomiya Akihiro Matsui Toru Miyazaki Masaaki Matsumoto Tsukasa Shimura Naotaka Murata Yasushi Komatsu Kazuki Tobita Yo Fujimoto Takahide Kodama Kenji Suzuki Hitoshi Anzai Kentaro Jujo Michiaki Higashitani 《Journal of cardiology》2021,77(2):109-115
BackgroundMalnutrition measured by the geriatric nutritional risk index (GNRI) was reported to be associated with poor prognosis for patients with peripheral artery disease (PAD). However, the optimal cut-off value of preprocedural GNRI for critical limb ischemia (CLI) and intermittent claudication (IC) is unknown. We aimed to determine its optimal cut-off value for CLI or IC patients requiring endovascular revascularization.MethodsWe explored data of 2246 patients (CLI: n = 1061, IC: n = 1185) registered in the Tokyo-taMA peripheral vascular intervention research COmraDE (TOMA-CODE) registry, which prospectively enrolled consecutive PAD patients who underwent endovascular revascularization in 34 hospitals in Japan from August 2014 to August 2016. The optimal cut-off values of GNRI were assessed by the survival classification and regression tree (CART) analyses, and the survival curve analyses for major adverse cardiovascular and limb events (MACLEs) were performed for these cut-off values.ResultsIn addition to the first cut-off value of 96.2 in CLI and 85.6 in IC, the survival CART provided an additional cut-off value of 78.2 in CLI and 106.0 in IC for further risk stratification. The survival curve was significantly stratified by the GNRI-based malnutrition status in both CLI [high risk: 47.7% (51/107), moderate: 30.1% (118/392), and low: 10.2% (53/520), log–rank p < 0.001] and IC [high risk: 14.3% (7/49), moderate: 4.5% (29/646), and low: 0.5% (2/407), log–rank p < 0.001]. The multivariate Cox-proportional hazard analysis showed that a higher GNRI was significantly associated with a better outcome in both CLI [hazard ratio (HR) per 1-point increase: 0.97, 95% CI: 0.96–0.98, p < 0.001] and IC (HR: 0.94, 95% CI: 0.91–0.97, p < 0.001).ConclusionsPreprocedural nutritional status significantly stratified future events in patients with PAD. Given that the optimal cut-off value of GNRI in CLI was almost 10-points lower than that of IC, using a disease-specific cut-off value is important for risk stratification. 相似文献
4.
5.
6.
Yasushi Sawayama Hidehiro Itonaga Takuya Fukushima Nobuaki Nakano Hiroshi Fujiwara Atae Utsunomiya Takahiro Fukuda Toshihiro Miyamoto Tetsuya Eto Kaname Miyashita Hirohisa Nakamae Masao Ogata Atsushi Yamanoha Yasuhiko Miyazaki Junya Kanda Yoshiko Atsuta Koji Kato ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation 《American journal of hematology》2019,94(5):E143-E146
7.
8.
Yasushi Yamasaki Keita Harada Shumpei Yamamoto Eriko Yasutomi Shotaro Okanoue Mami Hirai Shohei Oka Yuka Obayashi Hiroyuki Sakae Kenta Hamada Toshihiro Inokuchi Hideaki Kinugasa Yuusaku Sugihara Masahiro Takahara Takehiro Tanaka Sakiko Hiraoka Yoshiro Kawahara Hiroyuki Okada 《Digestive endoscopy》2020,32(5):791-800
9.
10.
ObjectivesWe sought to evaluate whether the cutaneous silent period (CSP) could be an electrophysiological indicator reflective of the effects of therapy for Parkinson's disease (PD), including anti-PD medications or deep brain stimulation (DBS).Material and MethodsWe recorded the CSP in 43 patients with PD prior to and following the administration of medication during a pre-DBS evaluation (30 cases) and the “on” and “off” states of subthalamic nucleus DBS (13 cases). The CSP was elicited from the abductor pollicis brevis muscle by an electrical stimulation of the index finger that was 2, 4, and 15 times stronger than the sensory threshold (ST). We measured changes in latencies, including the onset, duration, and end of CSP, and waveform scores from 0 to 3. The correlation between the CSP score and unified PD rating score part III (UPDRS-III) also was assessed.ResultsThe onset latency and duration of CSP were significantly different between high- (15ST) and low-strength stimulations (2ST and 4ST). However, there were no significant latency changes (onset, duration, end of CSP) before and after receiving medication, or during the on and off state of the DBS. Anti-PD medications substantially increased the CSP waveform score only in the 4ST state. However, the waveform score significantly increased in all stimuli states during the DBS-on state. Both medication and the DBS-on state decreased the UPDRS-III. Nevertheless, there was no statistically significant correlation between the UPDRS-III and CSP waveform scores.ConclusionDifferent onset latencies and the duration of CSP between low- and high-strength stimuli support the hypotheses proposing two different reflex pathways. Despite being independent from the UPDRS-III, the CSP may be an electrophysiological indicator reflective of the changes in inhibitory activity to the spinal α-motoneuron in response to anti-PD medications and DBS. 相似文献